Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme
- PMID: 8921103
- DOI: 10.1093/oxfordjournals.humrep.a019456
Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme
Abstract
We investigated the effect of endogenous gonadotrophins during pituitary desensitization with gonadotrophin-releasing hormone agonist (GnRHa) on ovarian responsiveness or the outcome of in-vitro fertilization (IVF) and embryo transfer. The results of 67 women who participated in the IFV programme at Nagasaki University Hospital, Japan, were analysed retrospectively. All women received GnRHa from the third day of menstrual cycle, and ovarian stimulation with exogenous gonadotrophins was initiated when the serum oestradiol concentration decreased to < 30 pg/ml. The serum follicle stimulating hormone (FSH)/luteinizing hormone (LH) ratio, rather than serum FSH or LH concentrations during GnRHa-induced pituitary desensitization, showed a significant positive correlation with age and the total dose of exogenous gonadotrophins. The FSH/LH ratio also showed a significant negative correlation with oestradiol response and the number of retrieved oocytes, and was significantly lower in pregnant women compared with the non-pregnant group during pituitary desensitization. Our results indicate that, even under pituitary desensitization with GnRHa, the serum FSH/LH ratio influences individual ovarian responsiveness and the state of the intra-ovarian hormonal environment. Our results suggest that the FSH/LH ratio may be a useful clinical predictor of the ovarian response to exogenous gonadotrophins under pituitary desensitization.
Similar articles
-
The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.Hum Reprod. 1996 Jun;11(6):1209-13. doi: 10.1093/oxfordjournals.humrep.a019357. Hum Reprod. 1996. PMID: 8671425 Clinical Trial.
-
Relative influence of serum follicle stimulating hormone, age and other factors on ovarian response to gonadotrophin stimulation.Br J Obstet Gynaecol. 1994 Nov;101(11):999-1002. doi: 10.1111/j.1471-0528.1994.tb13047.x. Br J Obstet Gynaecol. 1994. PMID: 7999732
-
Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).Hum Reprod. 1996 May;11(5):962-7. doi: 10.1093/oxfordjournals.humrep.a019332. Hum Reprod. 1996. PMID: 8671371 Clinical Trial.
-
Revisiting gonadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins.Hum Reprod Update. 1998 Jan-Feb;4(1):83-101. doi: 10.1093/humupd/4.1.83. Hum Reprod Update. 1998. PMID: 9622415 Review.
-
Tailoring FSH and LH administration to individual patients.Reprod Biomed Online. 2005 Sep;11(3):283-93. doi: 10.1016/s1472-6483(10)60835-8. Reprod Biomed Online. 2005. PMID: 16176666 Review.
Cited by
-
Differences in serum LH and FSH levels using depot or daily GnRH agonists in controlled ovarian stimulation: influence on ovarian response and outcome of ART.J Assist Reprod Genet. 2005 Aug;22(7-8):277-83. doi: 10.1007/s10815-005-5998-8. J Assist Reprod Genet. 2005. PMID: 16195824 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources